NCM Capital Management LLC Has $504,000 Holdings in CVS Health Co. (NYSE:CVS)

NCM Capital Management LLC boosted its position in shares of CVS Health Co. (NYSE:CVS) by 184.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,225 shares of the pharmacy operator’s stock after buying an additional 7,276 shares during the period. NCM Capital Management LLC’s holdings in CVS Health were worth $504,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. White Knight Strategic Wealth Advisors LLC increased its stake in shares of CVS Health by 176.0% in the 4th quarter. White Knight Strategic Wealth Advisors LLC now owns 15,740 shares of the pharmacy operator’s stock valued at $707,000 after purchasing an additional 10,038 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of CVS Health by 19.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 8,423,608 shares of the pharmacy operator’s stock valued at $378,136,000 after acquiring an additional 1,373,663 shares during the last quarter. Waverly Advisors LLC boosted its holdings in shares of CVS Health by 7.9% during the 4th quarter. Waverly Advisors LLC now owns 19,071 shares of the pharmacy operator’s stock valued at $856,000 after acquiring an additional 1,392 shares in the last quarter. Woodline Partners LP bought a new stake in CVS Health during the 4th quarter worth $2,451,000. Finally, Vivaldi Capital Management LP bought a new position in CVS Health in the fourth quarter valued at about $7,048,000. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Up 1.5%

CVS stock opened at $63.73 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The stock’s 50 day simple moving average is $66.48 and its 200 day simple moving average is $59.32. The company has a market cap of $80.62 billion, a P/E ratio of 17.41, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. The business had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter last year, the firm posted $1.31 EPS. CVS Health’s revenue was up 7.0% compared to the same quarter last year. On average, research analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were paid a dividend of $0.665 per share. The ex-dividend date was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.17%. CVS Health’s dividend payout ratio (DPR) is currently 63.48%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Morgan Stanley reiterated an “overweight” rating on shares of CVS Health in a report on Tuesday, April 15th. Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a report on Thursday, January 30th. Leerink Partnrs raised CVS Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 12th. Robert W. Baird increased their price target on CVS Health from $51.00 to $71.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Finally, Leerink Partners raised shares of CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the company from $55.00 to $75.00 in a research report on Thursday, February 13th. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.94.

Insiders Place Their Bets

In related news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.